Email this article Effect of cancer drugs in patients with metastatic colorectal cancer in terms of mortality reduction
- Authors: Fedyanin M.Y.1, Pokataev I.A.1, Sekhina O.V.1, Tryakin A.A.1, Tjulandin S.A.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 7, No 3 (2017)
- Pages: 11-15
- Section: ORIGINAL REPORTS
- Published: 07.12.2017
- URL: https://onco-surgery.info/jour/article/view/222
- DOI: https://doi.org/10.17650/2220-3478-2017-7-3-11-15
- ID: 222
Cite item
Full Text
Abstract
Background. Colorectal cancer (CRC) is the 4th most frequent cause of death among patients with malignant tumors worldwide. In 2012, approximately 1.3 million people were diagnosed with CRC, nearly 690 000 patients died.
Objective: to assess the impact of various chemotherapeutic drugs and monoclonal antibodies penetration on the dynamics of CRC-associated mortality in patients with metastatic CRC in Russia.
Materials and methods. We analyzed the mortality data for 2014 obtained from the National Cancer Register and the data from the Register of Chemotherapy Drugs (oxaliplatin, irinotecan, capecitabine) and Monoclonal Antibodies (bevacizumab, cetuximab, panitumumab) Procurement for cancer centers from 82 regions of Russia. We performed correlation and regression analysis to estimate the impact of various chemotherapeutic drugs and monoclonal antibodies penetration on the CRC-associated mortality, as well as the mortality from colon cancer and rectal cancer.
Results. We observed a correlation between the mortality reduction in patients with metastatic CRC and penetration of irinotecan (k = –0.324, р = 0.003), capecitabine (k = –0.223, p = 0.04), bevacizumab (k = –0.229, p = 0.04), panitumumab (k = –0.232, p = 0.04), any anti-EGFR monoclonal antibody (k = –0.201, p = 0.07) and all monoclonal antibodies (k = –0.256, p = 0.02). Regression analysis demonstrated a decreased mortality rates in patients receiving irinotecan (β = –0.26, р = 0.02), anti-EGFR monoclonal antibodies (β = –0.19, р = 0.09) and oxaliplatin or irinotecan (β = –0.2, р = 0.06).
Conclusion. Our results suggest a correlation between the administration of irinotecan and monoclonal antibodies and mortality reduction in patients with metastatic CRC.
About the authors
M. Yu. Fedyanin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: fedianinmu@mail.ru
23 Kashirskoe Shosse, Moscow 115478, Russia Russian Federation
I. A. Pokataev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia Russian Federation
O. V. Sekhina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia Russian Federation
A. A. Tryakin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia Russian Federation
S. A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Email: fake@neicon.ru
23 Kashirskoe Shosse, Moscow 115478, Russia Russian Federation
References
Supplementary files
